For Research and Laboratory Use Only
10% OFFMelanotan II (MT-2) is a synthetic analogue of alpha-melanocyte stimulating hormone. Research applications include studies on melanogenesis and photoprotection. 99% HPLC verified purity with full Certificate of Analysis. CAS #: 121062-08-6.
$50.00
$45.00
HPLC tested >99%
Fri, Apr 17 – Sun, Apr 19
For research and laboratory use only. Not for human consumption, therapeutic, or diagnostic use. Must be 21+ to purchase.
ERECTILE RESPONSE
17/20 vs 3/20 placebo
RIGIDITY DURATION
Mean tip rigidity >80%
TANNING EFFECT
UV-independent pigmentation
NON-TANNER FRIENDLY
Works despite genetic variants
MECHANISM OF ACTION
Melanotan II is a cyclic heptapeptide analog of α-MSH that binds melanocortin receptors, stimulating melanogenesis and activating central nervous system pathways.
Melanocortin-1 Receptor
Central Nervous System
From clinical studies and research protocols
Based on Barnetson 2006 RCT
0.010-0.025 mg/kg
Once daily SubQ
As needed
Maintenance dosing
·Subcutaneous injection preferred
·Effects accumulate over days
·Pigmentation persists weeks after cessation
PHARMACOKINETICS
Short half-life but cumulative pigmentation effects
Cyclic structure provides stability vs linear α-MSH
SAFETY PROFILE
FAQ
MT-II activates MC1R receptors on melanocytes, triggering cAMP-PKA signaling to stimulate eumelanin synthesis directly, bypassing UV-induced DNA damage. Works even in individuals with MC1R genetic variants.
·Research compound — not approved for human use
·Start with lower doses to assess tolerance
·Side effects are dose-dependent
·Reconstitute with bacteriostatic water
Energy Homeostasis
CLINICAL / RESEARCH RESULTS
Melanotan II induced tanning even in subjects with MC1R variant alleles who typically cannot tan from UV exposure alone.
100%
Showed melanin increase
Active treatment group
85%
Erectile response
17/20 vs 3/20 placebo
77
Subjects enrolled
Randomized controlled
RESEARCH APPLICATIONS
Melanin synthesis activation. UV-independent tanning through MC1R agonism.
Source: Barnetson 2006
85% clinical trial response rate via central MC4R activation.
Source: Wessells 1998
MC4R-mediated effect. Common observation in clinical studies.
Source: Dorr et al. 1996
Increased eumelanin production provides enhanced UV defense.
Source: Clinical data
Based on Wessells 1998 study
0.025 mg/kg
SubQ injection as needed
·Onset: 30-60 minutes
·Duration: 4-6 hours pro-erectile window
·Peak effects at 2-4 hours
Non-selective melanocortin receptor agonist
Increased pigmentation of existing nevi (moles) and freckles. Dermatological monitoring recommended.
·Side effects are dose-dependent
·Nausea typically resolves with continued use
·Monitor skin for concerning mole changes
·Seek medical attention for erections lasting >4 hours
COMPOUND INFORMATION
Lyophilized (powder)
Reconstituted
